GNLX (Genelux) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


GNLX Genelux Corp GNLX
28 GF Score
Price $2.93
! 4 Warning Signs
View Full Analysis

What is Genelux Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Genelux's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

GNLX vs ACOG, VTVT, SPRB: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Genelux's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genelux Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genelux's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Genelux's Margin of Safety % (DCF Earnings Based) falls into.


GNLX
28GF Score
Genelux Corp GNLX
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genelux Business Description

Address 2625 Townsgate Road, Suite 230, Westlake Village, CA, USA, 91361
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
28GF Score

Get the complete analysis for GNLX

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.93
Price